Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2017-06-01 Declaration of Voting R…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "Voting Rights Announcements" and contains sections detailing the "Notification of Major Holdings" under German Securities Trading Act (WpHG) regulations. It reports changes in voting rights thresholds crossed by a specific person (Mr Yuewen Zheng) and lists the resulting total positions in terms of voting rights percentages and absolute numbers. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing regulatory thresholds. The code for this is MRQ.
2017-06-01 English
Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept tender offer of CREAT Group
M&A Activity Classification · 100% confidence The document is a press release titled "Joint reasoned statement of Biotest AG – Management Board and Supervisory Board recommend to accept tender offer of CREAT Group". It explicitly references the German Securities Acquisition and Takeover Act (WpÜG) and discusses the fairness opinion regarding a tender offer from CREAT Group. This content directly relates to a takeover bid or merger proposal being evaluated by the target company's board. This aligns perfectly with the definition for M&A Activity (TAR). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific M&A event.
2017-06-01 English
DGAP-DD: Biotest AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: Biotest AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly matches the definition for Director's Dealing, which corresponds to the filing code DIRS. The document details the transaction (Acquisition), the person involved (Dr. Katrin Bernöster, Vice President), and the security involved.
2017-05-31 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details the acquisition/disposal of shares with voting rights, referencing specific sections of the German Securities Trading Act (WpHG, specifically Article 26, Section 1, and Sections 21, 22, 25). This type of filing reports changes in significant share ownership thresholds crossed by an individual or entity. This directly corresponds to the definition of 'Major Shareholding Notification' (Code: MRQ). Although the header mentions 'Voting Rights Announcements', the content is a formal notification of a change in holding percentage, which is the core function of an MRQ filing.
2017-05-24 English
Biotest AG: Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group
M&A Activity Classification · 100% confidence The document is a press release announcing the 'Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group'. This announcement details a takeover bid (tender offer) for the company's shares, including the offer price and acceptance period. This activity falls directly under the definition of M&A Activity (Takeover/Merger). The relevant code is TAR.
2017-05-18 English
Report Publication Announcement 2017
Report Publication Announcement Classification · 100% confidence The document is very short (1654 characters) and explicitly states that it is a 'Preliminary announcement of the publication of financial reports'. It details *when* the 'Financial report (half-year/Q2)' will be disclosed (August 14, 2017) and provides links to where the report will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement about the future publication of a report should be classified as a Report Publication Announcement (RPA), not the report itself (which would be an IR).
2017-05-17 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.